PT - JOURNAL ARTICLE AU - Sy Duong-Quy AU - Thong Hua-Huy AU - Nhu Doan-Quynh AU - Bao Nguyen-Quoc AU - Khiet Le-Quang AU - Dinh Tran-Thanh AU - Jean-Paul Homasson AU - Anh-Tuan Dinh-Xuan TI - A study of exhaled NO (FENO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country AID - 10.1183/13993003.congress-2015.PA5013 DP - 2015 Sep 01 TA - European Respiratory Journal PG - PA5013 VI - 46 IP - suppl 59 4099 - http://erj.ersjournals.com/content/46/suppl_59/PA5013.short 4100 - http://erj.ersjournals.com/content/46/suppl_59/PA5013.full SO - Eur Respir J2015 Sep 01; 46 AB - Introduction: Measurement of FENO is a useful tool for assessment of asthma patients who are treated withinhaled corticosteroids (ICS).Aims of study: This study was planned to assess the use of FENO measurement in therapeuticdecision making, disease control, and cost effectiveness for management of patients with asthma.Method: Patients with uncontrolled asthma with FENO> 25ppb, were included in this study. They were classified into 3 groups according to the intervention used to determine therapy: group 1 (Gr1): used GINA guidelines, group 2 (Gr2): used GINA plus FENO, andgroup 3 (Gr3): used only FENO.Result: 162 patients were included and randomly divided into 3 groups: Gr1: 48 patients (FeNO = 52 ± 12ppb), Gr2: 64 patients (FeNO = 54 ± 18 ppb), Gr3: 50 patients (FeNO = 53 ±16 ppb). Asthma control was achieved after 3 months for all 3 groups. At 9 months the percentage of patients on high-dose ICS in Gr1 > Gr3 > Gr2 (24%, 17%, 12%; respectively; p <0.01). At 18 months, 65% of patients of Gr2 were on low-dose CSI vs 54% in Gr1 and 42%in Gr3 (p <0.01); 56% patients in G3 were treated with medium dose of ICS vs 37% in Gr1 and 27% in Gr2 (p <0.001). After 18 months, total doses of ICS were significantly lower in theGr2 compared to Gr1 and Gr3. The number of exacerbations in the Gr2 < Gr3 <Gr1. The costof daily treatment was lower in patients in Gr2 compared to Gr1 and Gr3 (-55 USD at 9thmonth and -95 USD at 18th month).Conclusion: The use of FENO for titration of ICS dose in asthma patients helps to titrate down the dose of ICS and reduce the cost of treatment and thus provides a useful tool for the management of asthma in developing countries.